Lantheus Holdings, Inc. (LNTH): R&D Expense
$177.31M
Year ended 2025-12-31
$173.09M
Trailing 12 months to 2026-06-30
-17.1%
3-year compound annual growth
+40.2%
5-year compound annual growth
+28.6%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $177.31M | +5.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $168.10M | +116.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $77.71M | -75.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $311.68M | +593.1% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $44.97M | +37.1% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $32.79M | +63.8% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $20.02M | +17.3% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $17.07M | -5.8% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $18.12M | +48.5% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $12.20M | -15.0% | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $14.36M | +5.0% | 2018-02-26, From 2015-01-01 |
| 2014-12-31 | $13.67M | -55.1% | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | $30.46M | n/a | 2016-03-02, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $177.31M | +5.5% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $186.20M | -14.9% |
| Neogen Corp (NEOG) | 2026-05-31 | $18.40M | -12.8% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $106.80M | -5.8% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $251.21M | +14.3% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $388.86M | -16.6% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $2.20M | -20.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.04M | -22.0% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $2.88M | -11.9% |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗